New boxed warnings of clot risk ordered for immune globulin by FDA

06/13/2013 | Medscape (free registration)

The FDA authorized additional warning over the use of human immune globulin products after new data strengthened the connection between such products and thrombosis risk. Drugmakers will have to put additional risk information on the products' current boxed warning labels, while a box warning should be added to the labels of intramuscular and subcutaneous human immune globulin products. Additional data on risk mitigation strategies will also be a requirement.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA